Atopic dermatitis affects both children and adults. It is estimated to affect between 2% and 5% of the European population. Among adult patients with atopic dermatitis, nearly half suffer from a moderate form of the disease. Atopic dermatitis has a substantial impact on daily life and overall quality of life. Persistent itching is the most burdensome symptom. The objectives of the study are to describe the persistent burden and unmet medical needs in patients with uncontrolled moderate atopic dermatitis who have a contraindication or intolerance to topical corticosteroids and topical calcineurin inhibitors and estimate the proportion of patients with uncontrolled moderate atopic dermatitis who have a contraindication or intolerance to topical corticosteroids and topical calcineurin inhibitors.
